AbCellera Biologics Inc. Common Shares ABCL
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 2 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $12.86 (+1.6% upside)
Key Stats
- Today's Range
- $11.78 – $12.68
- 50-Day Range
- $4.98 – $13.18
- 52-Week Range
- $2.75 – $13.18
- Volume
- 4.99 million shs
- Average Volume
- 5.96 million shs
- Market Cap
- $4.10 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.57
- Price / Sales
- 61.95
Short Interest
- Short Interest
- 0.31%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $66.17 million
- Net Income
- $-164,656,000
- Net Margin
- -248.84%
- Return on Equity
- -18.38%
- Debt-to-Equity
- —
About AbCellera Biologics Inc. Common Shares
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Related Stocks
Compare head-to-head: ABCL vs LLY·ABCL vs JNJ·ABCL vs ABBV·ABCL vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.